{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:57:00Z","timestamp":1781686620662,"version":"3.54.5"},"reference-count":20,"publisher":"Norwegian Medical Association","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.21.0047","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T02:24:13Z","timestamp":1636597453000},"source":"Crossref","is-referenced-by-count":3,"title":["Amiodarone-induced thyrotoxicosis"],"prefix":"10.4045","volume":"141","author":[{"given":"Ole-Gunnar","family":"Anfinsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"ref=1","unstructured":"Anfinsen\u00a0OG, Lima\u00a0K, Nouri Sharikabad\u00a0M. \u00d8kende forbruk av amiodaron i Norge. Hjerteforum 2021; 34: 46\u20139."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Bartalena\u00a0L, Bogazzi\u00a0F, Chiovato\u00a0L et al. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J 2018; 7: 55\u201366. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29594056&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1159%2F000486957","DOI":"10.1159\/000486957"},{"key":"ref=3","unstructured":"Raicevic S, Koren-Dahll L. Nasjonal veileder i endokrinologi: Amiodarone og tyreoidea. https:\/\/www.endokrinologi.no\/ Lest 30.4.2021."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Haverkamp\u00a0W, Israel\u00a0C, Parwani\u00a0A. Klinische Besonderheiten der Therapie mit Amiodaron. Herzschrittmacherther Elektrophysiol 2017; 28: 307\u201316. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28643175&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00399-017-0516-0","DOI":"10.1007\/s00399-017-0516-0"},{"key":"ref=5","unstructured":"Folkehelseinstituttet. Fakta om jod. https:\/\/www.fhi.no\/ml\/kosthold\/fakta-om-jod\/ Lest 30.4.2021."},{"key":"ref=6","unstructured":"Platou\u00a0ES, Gjesdal\u00a0K. Historien om amiodaron. Hjerteforum 2011; 24: 119\u201322."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Basaria\u00a0S, Cooper\u00a0DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706\u201314. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15989900&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.amjmed.2004.11.028","DOI":"10.1016\/j.amjmed.2004.11.028"},{"key":"ref=8","unstructured":"Ross DS. Amiodarone and thyroid dysfunction. UpToDate. https:\/\/www.uptodate.com\/contents\/amiodarone-and-thyroid-dysfunction Lest 25.11.2020."},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Tomisti\u00a0L, Rossi\u00a0G, Bartalena\u00a0L et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol 2014; 171: 363\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24935933&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1530%2FEJE-14-0267","DOI":"10.1530\/EJE-14-0267"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Pattison\u00a0DA, Westcott\u00a0J, Lichtenstein\u00a0M et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun 2015; 36: 356\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25569865&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FMNM.0000000000000260","DOI":"10.1097\/MNM.0000000000000260"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Bogazzi\u00a0F, Tomisti\u00a0L, Rossi\u00a0G et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab 2009; 94: 3757\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19622616&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1210%2Fjc.2009-0940","DOI":"10.1210\/jc.2009-0940"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Huscher\u00a0D, Thiele\u00a0K, Gromnica-Ihle\u00a0E et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119\u201324. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18684744&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fard.2008.092163","DOI":"10.1136\/ard.2008.092163"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Yagishita\u00a0A, Hachiya\u00a0H, Kawabata\u00a0M et al. Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. Circ J 2013; 77: 2898\u2013903. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24042320&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1253%2Fcircj.CJ-13-0220","DOI":"10.1253\/circj.CJ-13-0220"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"O'Sullivan\u00a0AJ, Lewis\u00a0M, Diamond\u00a0T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154: 533\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16556715&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1530%2Feje.1.02122","DOI":"10.1530\/eje.1.02122"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Bogazzi\u00a0F, Miccoli\u00a0P, Berti\u00a0P et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002; 132: 1114\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12490863&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1067%2Fmsy.2002.128561","DOI":"10.1067\/msy.2002.128561"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Simsir\u00a0IY, Ozdemir\u00a0M, Duman\u00a0S et al. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine 2018; 62: 144\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29968224&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs12020-018-1661-x","DOI":"10.1007\/s12020-018-1661-x"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Uzan\u00a0L, Guignat\u00a0L, Meune\u00a0C et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 2006; 29: 231\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16524322&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165%2F00002018-200629030-00006","DOI":"10.2165\/00002018-200629030-00006"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Jaggarao\u00a0NSV, Sheldon\u00a0J, Grundy\u00a0EN et al. The effects of amiodarone on thyroid function. Postgrad Med J 1982; 58: 693\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7170269&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fpgmj.58.685.693","DOI":"10.1136\/pgmj.58.685.693"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Hermida\u00a0JS, Jarry\u00a0G, Tcheng\u00a0E et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 2004; 116: 345\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14984821&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.amjmed.2003.09.036","DOI":"10.1016\/j.amjmed.2003.09.036"},{"key":"ref=20","unstructured":"Hindricks\u00a0G, Potpara\u00a0T, Dagres\u00a0N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373\u2013498. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32860505&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Feurheartj%2Fehaa612"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Amiodaronindusert tyreotoksikose"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:18:52Z","timestamp":1781684332000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2021\/11\/klinisk-oversikt\/amiodaronindusert-tyreotoksikose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":20,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,11,9]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.21.0047","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}